Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors
dc.contributor.author | Pipe, Steven W. | |
dc.contributor.author | Hermans, Cédric | |
dc.contributor.author | Chitlur, Meera | |
dc.contributor.author | Carcao, Manuel | |
dc.contributor.author | Castaman, Giancarlo | |
dc.contributor.author | Davis, Joanna A. | |
dc.contributor.author | Ducore, Jonathan | |
dc.contributor.author | Dunn, Amy L. | |
dc.contributor.author | Escobar, Miguel | |
dc.contributor.author | Journeycake, Janna | |
dc.contributor.author | Khan, Osman | |
dc.contributor.author | Mahlangu, Johnny | |
dc.contributor.author | Meeks, Shannon L. | |
dc.contributor.author | Mitha, Ismail Haroon | |
dc.contributor.author | Négrier, Claude | |
dc.contributor.author | Nowak-Göttl, Ulrike | |
dc.contributor.author | Recht, Michael | |
dc.contributor.author | Chrisentery-Singleton, Tammuella | |
dc.contributor.author | Stasyshyn, Oleksandra | |
dc.contributor.author | Vilchevska, Kateryna V. | |
dc.contributor.author | Martinez, Laura Villarreal | |
dc.contributor.author | Wang, Michael | |
dc.contributor.author | Windyga, Jerzy | |
dc.contributor.author | Young, Guy | |
dc.contributor.author | Alexander, W. Allan | |
dc.contributor.author | Bonzo, Daniel | |
dc.contributor.author | Macie, Christopher | |
dc.contributor.author | Mitchell, Ian S. | |
dc.contributor.author | Sauty, Evelyne | |
dc.contributor.author | Wilkinson, Thomas A. | |
dc.contributor.author | Shapiro, Amy D. | |
dc.date.accessioned | 2022-08-02T18:59:15Z | |
dc.date.available | 2023-08-02 14:59:14 | en |
dc.date.available | 2022-08-02T18:59:15Z | |
dc.date.issued | 2022-07 | |
dc.identifier.citation | Pipe, Steven W.; Hermans, Cédric ; Chitlur, Meera; Carcao, Manuel; Castaman, Giancarlo; Davis, Joanna A.; Ducore, Jonathan; Dunn, Amy L.; Escobar, Miguel; Journeycake, Janna; Khan, Osman; Mahlangu, Johnny; Meeks, Shannon L.; Mitha, Ismail Haroon; Négrier, Claude ; Nowak-Göttl, Ulrike ; Recht, Michael; Chrisentery-Singleton, Tammuella ; Stasyshyn, Oleksandra; Vilchevska, Kateryna V.; Martinez, Laura Villarreal; Wang, Michael; Windyga, Jerzy; Young, Guy; Alexander, W. Allan; Bonzo, Daniel; Macie, Christopher; Mitchell, Ian S.; Sauty, Evelyne; Wilkinson, Thomas A.; Shapiro, Amy D. (2022). "Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors." Haemophilia 28(4): 548-556. | |
dc.identifier.issn | 1351-8216 | |
dc.identifier.issn | 1365-2516 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/173146 | |
dc.description.abstract | IntroductionEptacog beta is a new recombinant activated human factor VII bypassing agent approved in the United States for the treatment and control of bleeding in patients with haemophilia A or B with inhibitors 12 years of age or older.AimTo prospectively assess in a phase 3 clinical trial (PERSEPT 2) eptacog beta efficacy and safety for treatment of bleeding in children <12 years of age with haemophilia A or B with inhibitors.MethodsUsing a randomised crossover design, subjects received initial doses of 75 or 225 μg/kg eptacog beta followed by 75 μg/kg dosing at predefined intervals (as determined by clinical response) to treat bleeding episodes (BEs). Treatment success criteria included a haemostasis evaluation of ‘excellent’ or ‘good’ without use of additional eptacog beta, alternative haemostatic agent or blood product, and no increase in pain following the first ‘excellent’ or ‘good’ assessment.ResultsTreatment success proportions in 25 subjects (1–11 years) who experienced 546 mild or moderate BEs were 65% in the 75 μg/kg initial dose regimen (IDR) and 60% in the 225 μg/kg IDR 12 h following initial eptacog beta infusion. By 24 h, the treatment success proportions were 97% for the 75 μg/kg IDR and 98% for the 225 μg/kg IDR. No thrombotic events, allergic reactions, neutralising antibodies or treatment-related adverse events were reported.ConclusionBoth 75 and 225 μg/kg eptacog beta IDRs provided safe and effective treatment and control of bleeding in children <12 years of age. | |
dc.publisher | National Hemophilia Foundation | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.subject.other | haemophilia | |
dc.subject.other | eptacog beta | |
dc.subject.other | recombinant FVIIa | |
dc.subject.other | paediatric | |
dc.subject.other | inhibitors | |
dc.subject.other | PERSEPT | |
dc.title | Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors | |
dc.type | Article | |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Oncology and Hematology | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/173146/1/hae14563.pdf | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/173146/2/hae14563_am.pdf | |
dc.identifier.doi | 10.1111/hae.14563 | |
dc.identifier.source | Haemophilia | |
dc.identifier.citedreference | Walsh CE, Jimenez-Yuste V, Auerswald G, Grancha S. The burden of inhibitors in haemophilia patients. Thromb Haemost. 2016; 116 (Suppl. 1 ): S10 - 17. | |
dc.identifier.citedreference | Neufeld EJ, Recht M, Sabio H, et al. Effect of acute bleeding on daily quality of life assessments in patients with congenital hemophilia with inhibitors and their families: observations from the dosing observational study in hemophilia. Value Health. 2012; 15 ( 6 ): 916 - 925. | |
dc.identifier.citedreference | Scalone L, Mantovani LG, Mannucci PM, Gringeri A, COCIS Study Investigators. Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors. Haemophilia. 2006; 12 ( 2 ): 154 - 162. | |
dc.identifier.citedreference | Klitgaard T, Nielsen TG. Overview of the human pharmacokinetics of recombinant activated factor VII. Br J Clin Pharmacol. 2008; 65 ( 1 ): 3 - 11. | |
dc.identifier.citedreference | Villar A, Aronis S, Morfini M, et al. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia. 2004; 10 ( 4 ): 352 - 359. | |
dc.identifier.citedreference | Santagostino E, Morfini M, Rocino A, Baudo F, Scaraggi F, Gringeri A. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors. Thromb Haemost. 2001; 86 ( 10 ): 954 - 958. | |
dc.identifier.citedreference | Gruppo RA, Kessler CM, Neufeld EJ, Cooper DL. Assessment of individual dose utilization vs. physician prescribing recommendations for recombinant activated factor VII (rFVIIa) in paediatric and adult patients with congenital haemophilia and alloantibody inhibitors (CHwI): the Dosing Observational Study in Hemophilia (DOSE). Haemophilia. 2013; 19 ( 4 ): 524 - 532. | |
dc.identifier.citedreference | Young G, Shapiro AD, Walsh CE, Gruppo RA, Gut RZ, Cooper DL. Patient/caregiver-reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE). Haemophilia. 2012; 18 ( 3 ): 392 - 399. | |
dc.identifier.citedreference | Valentino LA, Walsh CE, Reding MT, Young GA, Levendoglu-Tugal O, Cooper DL. Patient- and caregiver-reported bleeding symptoms and reasons for starting and stopping treatment with recombinant factor VIIa: analysis of the Dosing Observational Study in Haemophilia (DOSE). Haemophilia. 2012; 18 ( 4 ): 554 - 560. | |
dc.identifier.citedreference | Amby LK, Seremetis S, Obergfell A, Bjerre J. Challenges of defining reliable clinical surrogate end points in haemophilia trials: a critical review. Blood Coagul Fibrinolysis. 2009; 20 ( 7 ): 488 - 493. | |
dc.identifier.citedreference | World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013; 310 ( 20 ): 2191 - 2194. | |
dc.identifier.citedreference | Humphries TJ, Kessler CM. The challenge of pain evaluation in haemophilia: can pain evaluation and quantification be improved by using pain instruments from other clinical situations? Haemophilia. 2013; 19 ( 2 ): 181 - 187. | |
dc.identifier.citedreference | Ducore J, Lawrence JB, Simpson M, et al. Safety and dose-dependency of eptacog beta (activated) in a dose escalation study of non-bleeding congenital haemophilia A or B patients, with or without inhibitors. Haemophilia. 2017; 23 ( 6 ): 844 - 851. | |
dc.identifier.citedreference | Escobar M, Castaman G, Boix SB, et al. The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors. Haemophilia. 2021; 27 ( 6 ): 921 - 931. | |
dc.identifier.citedreference | Shapiro AD, Mitchell IS, Nasr S. The future of bypassing agents for hemophilia with inhibitors in the era of novel agents. J Thromb Haemost. 2018; 16 ( 12 ): 2362 - 2374. | |
dc.identifier.citedreference | Meeks SL, Leissinger CA. The evolution of factor VIIa in the treatment of bleeding in haemophilia with inhibitors. Haemophilia. 2019; 25 ( 6 ): 911 - 918. | |
dc.identifier.citedreference | Astermark J, Donfield SM, DiMichele DM, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood. 2007; 109 ( 2 ): 546 - 551. | |
dc.identifier.citedreference | Wang M, Lawrence JB, Quon DV, et al. PERSEPT 1: a phase 3 trial of activated eptacog beta for on-demand treatment of haemophilia inhibitor-related bleeding. Haemophilia. 2017; 23 ( 6 ): 832 - 843. | |
dc.identifier.citedreference | Chevreux G, Tilly N, Leblanc Y, et al. Biochemical characterization of LR769, a new recombinant factor VIIa bypassing agent produced in the milk of transgenic rabbits. Haemophilia. 2017; 23 ( 4 ): e324 -e334. | |
dc.identifier.citedreference | Medical and Scientific Advisory Council (MASAC). MASAC Recommendations Concerning Products Licensed for the Treatment of Hemophilia and Other Bleeding Disorders. MASAC Document #263. National Hemophilia Foundation; 2020. | |
dc.identifier.citedreference | Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med. 2017; 377 ( 9 ): 809 - 818. | |
dc.identifier.citedreference | Négrier C, Gomperts ED, Oldenburg J. The history of FEIBA: a lifetime of success in the treatment of haemophilia complicated by an inhibitor. Haemophilia. 2006; 12 ( s5 ): 4 - 13. | |
dc.identifier.citedreference | Hedner U. Recombinant activated factor VII: 30 years of research and innovation. Blood Rev. 2015; 29 (Suppl 1 ): S4 - 8. | |
dc.identifier.citedreference | SEVENFACT® [Package Insert]. Louisville, KY: HEMA Biologics, LLC; 2020. | |
dc.identifier.citedreference | Astermark J, Holstein K, Abajas YL, et al. The B-natural study-The outcome of immune tolerance induction therapy in patients with severe haemophilia B. Haemophilia. 2021; 27 ( 5 ): 802 - 813. | |
dc.identifier.citedreference | Ljung R, Auerswald G, Benson G, et al. Inhibitors in haemophilia A and B: management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients. Eur J Haematol. 2019; 102 ( 2 ): 111 - 122. | |
dc.identifier.citedreference | Male C, Andersson NG, Rafowicz A, et al. Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study. Haematologica. 2021; 106 ( 1 ): 123 - 129. | |
dc.identifier.citedreference | Astermark J. Overview of inhibitors. Semin Hematol. 2006; 43 (Suppl 4): S3 - 7. | |
dc.identifier.citedreference | Zanon E, Pasca S. Intracranial haemorrhage in children and adults with haemophilia A and B: a literature review of the last 20 years. Blood Transfus. 2019; 17 ( 5 ): 378 - 384. | |
dc.identifier.citedreference | Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020; 26 (Suppl 6 ): 1 - 158. | |
dc.working.doi | NO | en |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.